Our analysis of TP53 mutations in relation to the clinical characteristics and pathological features of gastric adenocarcinomas in the present study population is supported by pivotal studies on the molecular classification of gastric cancer [30]. This evidence concerns the gene TP53 and gastric adenocarcinoma.